Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Feature Assessment Study for Indications Based Programming (FASt-IBP)

This study has been completed.
Guidant Corporation
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: July 7, 2008
Last updated: February 17, 2017
Last verified: February 2017
The purpose of this evaluation is to assess the acceptance level of specific programming recommendations based on the patient's clinical needs and primary indications when using the feature 'Indications Based Programming' (IBP) available in the ZOOMVIEW Software Application for the TELIGEN DR / VR and COGNIS family of devices compared to daily life programming chosen by physicians.

Condition Intervention
Ventricular Tachycardia
Ventricular Flutter
Ventricular Fibrillation
Heart Failure
Device: Cognis 100-D, Teligen DR and VR 100 HE

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Feature Assessment Study for Indications Based Programming

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Proportion of patients that are programmed by the physician to anything other than the recommended IBP setting [ Time Frame: 6 Months ]

Secondary Outcome Measures:
  • - Degree of acceptance of IBP - Proportion parameters changed per patient - Differences between recommended and final programmed parameters - Total number of parameter changes from IBP recommendations - Frequency of changes made to a single parameter [ Time Frame: 6 Months ]

Enrollment: 301
Study Start Date: June 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
Device: Cognis 100-D, Teligen DR and VR 100 HE
Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.

Detailed Description:

"This study will focus on documenting the final parameter changes that are made in comparison to the IBP recommendations for a specific cardiovascular and arrhythmia history. It will therefore compare the device settings that were finally programmed during the last available follow up procedure to the last available parameter recommendations of IBP. IBP was designed to facilitate programming by providing customized parameter settings based on a patient's clinical needs and primary indication.

In order to further enhance the IBP feature for future device generations, additional data may be collected and evaluated on:

  • Physician perception and satisfaction with the New User Interface (NUI) of the programming application;
  • Motivation for adapting IBP recommendations for the final programming of the device;
  • Device data that can be retrieved from patient data disks that may include but is not limited to, arrhythmia episode detail, pacing counter data; total and individual therapy data"

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients indicated for the implant of an cardioverter defibrillator or cardiac resynchronization defibrillator defibrillator.

Inclusion Criteria:

  • indicated for implantation of an ICD or CRT-D device according local hospital implant criteria guidelines

    • Implanted or intended to be implanted with any CE-marked device approved for implant from the TELIGEN (single or dual chamber ICD) or COGNIS (CRT-D) family during first implant (no replacements)
    • Geographically stable patients who are available for follow-up at a study centre
    • Age 18 or above, or of legal age to give informed consent specific to national law

Exclusion Criteria:

Inability or refusal to sign the Patient Informed Consent

  • Pregnant or planning to become pregnant
  • Replacement device
  • Enrolment in another clinical trial, study or evaluation
  • Estimated life expectancy of less than six months per discretion of physician
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00711893

KH der Elisabethinen Linz
Linz, Austria, 4010
KH der Barmherzigen Schwestern Ried/Innkreis
Ried, Austria, 4910
Hartcentrum Hasselt - Dienst Cardiologie
Hasselt, Belgium, 3500
China, Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong, China
EHRU de Brest - Hospital de la Cavale Blanche
Brest, France, 29200
CHU Dijon - Hospital du Bocage
Dijon, France, 21000
CHR Orléans - Hospital la Source
Orléans, France, 45067
CMC Parly II
Parly, France, 78000
CHU de St. Etienne-Hospital Nord
Saint Priest en Jarez, France, 42055
CHU de Tours
Tours Cedex, France, 37044
Kerckhoff-Klinik GmbH
Bad Nauheim, Germany, 61231
Praxis Dres. Bischoff/Lang
Erfurt, Germany, 99084
Klinikum Fulda
Fulda, Germany, 36043
Marienhospital Herne
Herne, Germany, 44625
Klinikum Kassel
Kassel, Germany, 34125
Praxis Schnabel der Praxisgemeinschaft Kardiologie Meissen
Meissen, Germany, 01662
Klinikum Nuernberg
Nuernberg, Germany, 90471
Klinikum Dorothea Christiane Erxleben Quedlinburg GmbH
Quedlinburg, Germany, 06484
University Hospital of Heraklion
Heraklion, Greece, 71409
Paul Stradina Clinical University Hospital
Riga, Latvia, 1002
Ziekenhius Rijnstate Arnhem
Arnhem, Netherlands, 6815
Amphia Ziekenhius Breda
Breda, Netherlands, 4818
Narodny ustav srdcvych a cievnych chorob
Bratislava, Slovakia, 83348
Hospital Universitario Central de Asturias
Oviedo, Spain, 33006
Hospital Son Llatzer
Palma de Mallorca, Spain, 07004
Clinico Universitario de Valladolid
Valladolid, Spain, 47005
Centro Miguel Servet
Zaragoza, Spain, 50012
University Hospital of Geneva
Geneva, Switzerland, 1211
Sponsors and Collaborators
Boston Scientific Corporation
Guidant Corporation
Principal Investigator: Konrad Goehl, MD Klinikum Nuernberg
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT00711893     History of Changes
Other Study ID Numbers: FASt-IBP 0408
feci 08/1644
Study First Received: July 7, 2008
Last Updated: February 17, 2017

Additional relevant MeSH terms:
Heart Failure
Tachycardia, Ventricular
Ventricular Fibrillation
Ventricular Flutter
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes processed this record on April 21, 2017